|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Estimation of the Youden Index and its associated cutoff point显示文摘 | Fluss R Faraggi D Reiser B | 2005 | Biota J2005，47，： | 1 |
| 2 | Comparing the areas under two correlated ROC curves:parametric and nonparametric approaches显示文摘 | Molodianovitch K Faraggi D Reiser B | 2006 | Biom J2006，48，5： | 1 |
| 3 | Estimation of the Youden Index and its associated cut-off point显示文摘 | Fluss R Faraggi D Reiser B | 2005 | Biom J2005，47，： | 1 |
| 4 | Estimation of the area under the ROC curve显示文摘 | Faraggi D Reiser B | 2002 | Stat Med2002，21，20： | 1 |
| 5 | Dexamethason,etoposide,ifosfamide,and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma显示文摘 | Haim N Ben-Shahar M Faraggi d | 1997 | Cancer1997，10，： | 1 |
| 6 | Dexamethasone, etopo- side, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin' s lymphoma显示文摘 | Haim N Ben-Shahar M Faraggi D | 1997 | Cancer1997，80，10： | 1 |
| 7 | Comparing the areas under two correlated ROC curves:parametric and non-parametric approaches显示文摘 | Molodianovitch K Faraggi D Reiser B | 2006 | Biom J2006，48，5： | 1 |
| 8 | Dexamethasone, etoposide, ifosfamide, andcisplatin as second-line therapy in patientswith aggressive non-Hodgkin’s lymphoma显示文摘 | HAIM N BEN-SHAHAR M FARAGGI D | 1997 | Cancer1997，80，10： | 1 |
| 9 | Comparing the areas under two correlated ROC curves: parametric and non-parametric approaches显示文摘 | Molodianovitch K Faraggi D Reiser B | 2006 | Biom J2006，48，5： | 1 |
| 10 | 201'TI and 99mTc - MIBI gated SPECT in patients with large perfusion defect and left ventricular dysfunction:Comparison with equilibrium radionuclide an giography显示文摘 | Manrique A Faraggi M Vilain D | 1999 | J Nucl Med1999，40，： | 1 |
| 11 | Minima and best linear combination of oxidative stress and an lioxidam biomarkers to discriminate cardiovascular dis case显示文摘 | Schisterrrmn EF Faraggi D Bvowne R | 2002 | Netab eardiovasc Dis2002，12，5： | 1 |
| 12 | Estimation of the Youden Index and its associated cutoff point显示文摘 | Fluss R Faraggi D Reiser B | 2005 | Biom J2005，47，4： | 1 |
| 13 | Dexamethasone,etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma显示文摘 | Ben-Shahar M Faraggi D | 1997 | Cancer1997，80，10： | 1 |
| 14 | Relationship between resting 201T1 reverse redistribution, microvascular perfusion and functional recovery in acute myocardial infarction显示文摘 | Faraggi M Karila - Cohen D Brochet E | 2000 | J Nucl Med2000，41，3： | 1 |
| 15 | ROC analysis for markers with mass at zero显示文摘 | Schisterman EF Reiser B Faraggi D | 2006 | Stat Med2006，25，4： | 1 |
| 16 | Youden Index and the optimal threshold for markers with mass at zero显示文摘 | Schisterman EF Faraggi D Reiser B | 2008 | Stat Med2008，27，2： | 1 |
| 17 | Relationship between resting 201Tl reverse redistribution,microvascular perfusion,and functional recovery in acute myocardial in farction显示文摘 | Karila-Cohen D Brochet E | 2000 | J Nucl Med2000，41，3： | 1 |
| 18 | Minimal and best linear combination of oxidative stress and antioxidant biomarkers to discriminate cardiovascular disease显示文摘 | Schisterman EF Faraggi D Browne R | 2002 | Nutr Metab Cardiovasc Dis2002，12，5： | 1 |
| 19 | Bayesian variable selection method for censored survival data显示文摘 | Faraggi D Simon R | 1998 | Biometrics1998，54，： | 1 |
| 20 | Dexamethasone,etopo-side,ifosfamide and cisplatin as second 一 line therapy in patientswith aggressive non - Hodgkins lymphoma 显示文摘 | Haim N Ben - Shahar M Faraggi D | 1997 | Cancer1997，80，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员